Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) on Wednesday introduced NovoCare Pharmacy, a direct-to-patient delivery service offering all dose strengths of Wegovy (semaglutide) for USD499 per month to cash-paying patients in the United States.

This initiative supports uninsured individuals and those with commercial insurance that does not cover obesity treatments.

The launch follows the FDA's confirmation that Wegovy supply shortages have been resolved, ensuring sufficient availability to meet US demand. NovoCare Pharmacy is designed to provide convenient home delivery through CenterWell Pharmacy.

Beyond delivery, NovoCare offers benefit verification, refill reminders and live support from case managers to assist patients. The service ensures access to FDA-approved Wegovy, mitigating risks associated with compounded semaglutide from unregulated sources.

Novo Nordisk plans to extend the USD499 pricing offer to cash-paying patients using traditional retail pharmacies.

Wegovy is an FDA-approved treatment for obesity and cardiovascular risk reduction in eligible patients.